Biogen gets mixed decision at FDA AdComm on failed ALS drug as experts back
- Biogen gets mixed decision at FDA AdComm on failed ALS drug as experts back conditional, not full, approval FierceBiotech
- Biogen Stock Pops — But Ionis Stock Dips — On Mixed FDA View For ALS Drug Investor’s Business Daily
- Pharmalittle: FDA panel backs conditional approval for Biogen ALS drug; pharma fights tactic for lowering specialty med costs STAT
- FDA Issues Draft Guidance Aimed At Improving Oncology Clinical Trials For Accelerated Approval – SPDR S&P 500 (ARCA:SPY) Benzinga
- FDA Panel Supports Tofersen for Rare Genetic ALS Medpage Today
- View Full Coverage on Google News
Read More: Biogen gets mixed decision at FDA AdComm on failed ALS drug as experts back